Windtree Q2 net loss $12M ($20.91/shr), istaroxime data expected Q3 2024

WINDTREE THERAPEUTICS INC /DE/

Net loss of $12.0M ($20.91 per share) on 0.6M shares; operating loss $11.5M vs. $6.8M in Q2 2023.
R&D expense $9.9M (incl. $7.5M non-cash Varian asset acquisition cost) vs. $1.8M; G&A $1.6M vs. $2.4M.
Cash $1.8M, current liabilities $8.8M; substantial doubt about going concern disclosed.
Closed July transactions for $13.9M gross proceeds ($4.4M new funding, $9.5M note extinguishment); $35M equity line secured.
Istaroxime Phase 2 SEISMiC study enrollment near complete, topline by end of Q3 2024; board added Saundra Pelletier, Jed Latkin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.